Medicine and Dentistry
Endoscopic Retrograde Cholangiopancreatography
100%
Neoplasm
95%
Cholestasis
84%
Overall Survival
75%
Gemcitabine
68%
Biliary Tract Drainage
56%
Intraductal Papillary Mucinous Tumor
52%
Acute Pancreatitis
49%
Pancreatitis
46%
Pancreas Adenocarcinoma
46%
Cholangiocarcinoma
45%
Common Bile Duct Stone
44%
Endoscopic Ultrasound
39%
Metastatic Carcinoma
37%
Endoscopic Sphincterotomy
36%
Pancreas Islet Cell Tumor
35%
Prognostic Factor
35%
Stent Placement
35%
Self-Expandable Metallic Stent
35%
Computer Assisted Tomography
33%
Neuroendocrine Tumor
33%
Capsule Endoscopy
32%
Gallbladder Cancer
31%
Autoimmune Pancreatitis
31%
Cholangitis
29%
Recurrent Disease
28%
Hepatocellular Carcinoma
28%
Endoscopic Ultrasound Guided Fine Needle Biopsy
27%
Hazard Ratio
27%
Multidetector Computed Tomography
26%
Clinical Feature
26%
Obstructive Jaundice
25%
Cystic Pancreatic Lesion
25%
Adenocarcinoma
23%
Retrospective Cohort Study
22%
Cohort Analysis
22%
Stricture
21%
Endoscopic Papillotomy
20%
Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
20%
Pancreatic Duct
20%
Chronic Pancreatitis
20%
Conservative Treatment
19%
Liver Transplantation
19%
In-Stent Restenosis
19%
Odds Ratio
18%
Polyp
18%
Endoscopy
18%
Gene Mutation
18%
Common Bile Duct
18%
Biliary Tract Cancer
18%
Pharmacology, Toxicology and Pharmaceutical Science
Gemcitabine
94%
Overall Survival
52%
Neoplasm
42%
Acute Pancreatitis
41%
Pancreatitis
39%
Pancreas Adenocarcinoma
33%
Combination Therapy
22%
Common Bile Duct Stone
22%
Oxaliplatin
22%
Fluorouracil
21%
Bile Duct Carcinoma
20%
Progression Free Survival
20%
Cohort Study
18%
Ceruletide
15%
Pancreas Islet Cell Tumor
14%
Cholangitis
14%
Gallbladder Cancer
14%
Acute Cholecystitis
14%
Chronic Pancreatitis
13%
Recurrent Disease
12%
Paclitaxel
12%
Folinic Acid
12%
Acalculous Cholecystitis
11%
Fisetin
11%
Guggulsterone
11%
Clinical Feature
11%
Neuroendocrine Tumor
11%
Biliary Tract Cancer
11%
Tumor Growth
11%
Alternative Complement Pathway C3 C5 Convertase
11%
Nuclear Factor
11%
Cisplatin
11%
Gallstone
9%
Second-Line Chemotherapy
9%
Ursodeoxycholic Acid
8%
Nafamstat Mesilate
8%
Intraductal Papillary Mucinous Tumor
8%
Crohn's Disease
8%
Irinotecan
8%
Prevalence
8%
Biological Marker
8%
Survival Rate
8%
Diabetes Mellitus
7%
Western Blot
7%
Tumor Marker
7%
Obstructive Jaundice
7%
Cancer Staging
7%
Cytotoxicity
7%
Bleeding
7%
Capecitabine
6%